This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Photodynamic therapy for warts

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

DOUBLE-BLIND TRIAL

This double-blind, randomised trial compared the efficacy of photodynamic therapy with topical pre-treatment with 5-aminolaevulinic acid or placebo.

Patients had recalcitrant warts which had proved resistant to standard first-line treatment. 232 warts on 45 patients were entered into the trial.

Endpoints were:

  • wart size measured from photographs taken at entry then weeks 7, 14 & 18
  • pain score

A clearance rate of 56% was achieved with photodynamic therapy.

Notes:

  • all warts in this study, both in the placebo group and the treatment group, were also treated with paring and topical salicylic acid
  • adverse effects included itching and burning during therapy as well as pain during and following treatment and formation of blisters

Reference:

  1. Stender, I-M, Na, R. et al.. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet 2000; 355: 963-66.
  2. Prescriber 2004; 5(24):36-44.

Related pages

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.